Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Bullboard (CSE:AGN)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Comment by C10H12N2on Feb 16, 2023 3:06pm

RE:DMT For Stroke Found Safe to Proceed to the Next Trial Phase

It's moving to the NEXT PHASE OF PHASE 1 NOT TO PHASE 2. Just goofy stuff here.
49
Discussion
Post by Justdosomeddon Feb 16, 2023 2:43pm

DMT For Stroke Found Safe to Proceed to the Next Trial Phase

As expected, AGN.c's DMT for stroke phase 1 trial went well and was found safe to proceed to phase 2 trials. AGN’s safety review committee has also approved moving the study forward with the next ...more  
188
Discussion
Post by C10H12N2on Feb 14, 2023 9:26am

List of companies that have royally screwed over AGN to date

Cannabix Technologies Inc. Growmax Resources Inc. Coloured Ties Capital Inc. First Responder Technologies Inc. Algernon Neuroscience Inc. If you don't know you need to ask somebody.
220
Post by Whalewatcher1on Feb 13, 2023 9:31am

Algernon's financials?

What are others thoughts on the Algernon’s financial statements issued a few weeks ago? I keep wonder how these guys stay alive.  As of Nov 30 had $2.2M current payables, burning $1.8M per ...more  
394
Post by stockpatrolon Feb 09, 2023 4:15pm

Strokes can have devastating effects on the body, but new re

Strokes can have devastating effects on the body, but new research suggests that DMT may offer a potential treatment option. $AGN.c is currently in phase 1 clinical trials of DMT treatment for stroke, ...more  
657
Post by stockpatrolon Feb 08, 2023 5:12pm

$AGN.c is taking steps forward with their clinical trials. U

$AGN.c is taking steps forward with their clinical trials. Using data from phase 1 DMT trials for stroke treatment, to launch phase 2 study for Q3 2023. In the same quarter, a phase 2b study of ...more  
439
Post by stockpatrolon Feb 07, 2023 4:44pm

Algernon Pharmaceuticals is a company that is doing two impo

Algernon Pharmaceuticals is a company that is doing two important studies right now. One is a study to see if a drug called DMT is safe and works to treat stroke. The other study is to see if a drug ...more  
140
Comment by C10H12N2on Feb 07, 2023 12:14pm

RE:RE:AGN.c upcoming milestones

Without an uplist to NASDAQ this stock will most likely remain in the gutter. People want to see data and uplist ro NASDAQ. They have been royally screwed with the 100 to 1 reverse spilit based on an ...more  
103
Discussion
Comment by waves1on Feb 06, 2023 4:19pm

RE:AGN.c upcoming milestones

With one study in progress and another incoming, AGN is has an established plan for this year and could easily see some catalysts here. 
74
Discussion
Post by C10H12N2on Feb 05, 2023 3:43pm

Experts Fear Bird Flu Outbreak Could Turn Into New Pandemic

The spread of the avian influenza virus on a mink farm in Spain has some scientists on edge. “This is an infection that has epidemic and pandemic potential,” Dr. Isaac Bogoch, a Toronto-based ...more  
219
Discussion
Post by StockDoctor101on Feb 03, 2023 2:46pm

AGN.c upcoming milestones

Lot of upcoming milestones which could get AGN moving. Look out for data from phase 1 of the DMT study in Q2 of this year along with the beginning of a phase 2b IPF study for chronic cough also set ...more  
160
Discussion
Post by SkywalkerofLukeon Feb 02, 2023 2:28pm

CEO Interview on Ifenprodil for Chronic Cough

New interview with AGN.c AGNPF CEO (up 5% today). Gives updates on the previously announced 180 patient, 90-day Phase 2b clinical study of Ifenprodil for chronic cough that will begin in Q3. The ...more  
164
Post by C10H12N2on Feb 01, 2023 6:36pm

The CEO Wants You To Believe It's Current Market Conditions.

The CEO claims all your woes are because Penny Stock Investors @ CSE & OTC are stupid people. The CEO has stated the same thing in the recent past then retracted. Says he was misunderstood. Yet ...more  
161
Discussion
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities